PubAg

Main content area

PMIDA-Modified Fe3O4 Magnetic Nanoparticles: Synthesis and Application for Liver MRI

Author:
Demin, Alexander M., Pershina, Alexandra G., Minin, Artem S., Mekhaev, Alexander V., Ivanov, Vladimir V., Lezhava, Sofiya P., Zakharova, Alexandra A., Byzov, Iliya V., Uimin, Mikhail A., Krasnov, Victor P., Ogorodova, Ludmila M.
Source:
Langmuir 2018 v.34 no.11 pp. 3449-3458
ISSN:
1520-5827
Subject:
Fourier transform infrared spectroscopy, X-ray diffraction, hydrodynamics, iron oxides, light scattering, liver, magnetic properties, magnetic resonance imaging, magnetism, nanoparticles, pH, temperature, thermogravimetry, transmission electron microscopy
Abstract:
The surface modification of Fe₃O₄-based magnetic nanoparticles (MNPs) with N-(phosphonomethyl)iminodiacetic acid (PMIDA) was studied, and the possibility of their use as magnetic resonance imaging contrast agents was shown. The effect of the added PMIDA amount, the reaction temperature and time on the degree of immobilization of this reagent on MNPs, and the hydrodynamic characteristics of their aqueous colloidal solutions have been systematically investigated for the first time. It has been shown that the optimum condition for the modification of MNPs is the reaction at 40 °C with an equimolar amount of PMIDA for 3.5 h. The modified MNPs were characterized by X-ray diffraction, transmission electron microscopy, Fourier transform infrared spectroscopy, thermogravimetric, and CHN elemental analyses. The dependence of the hydrodynamic characteristics of the MNP colloidal solutions on the concentration and pH of the medium was studied by the dynamic light scattering method. On the basis of the obtained data, we can assume that the PMIDA molecules are fixed on the surface of the MNPs as a monomolecular layer. The modified MNPs had good colloidal stability and high magnetic properties. The calculated relaxivities r₂ and r₁ were 341 and 102 mmol–¹ s–¹, respectively. The possibility of using colloidal solutions of PMIDA-modified MNPs as a T₂ contrast agent for liver studies in vivo (at a dose of 0.6 mg kg–¹) was demonstrated for the first time.
Agid:
6071578